What makes HER2 an effective cancer target?
There are several reasons for HER2 receptor to become an important therapeutic target for cancer therapy. First, upregulated HER2 level causes tumoregenesis and the level of HER2 gene expression is much higher in cancer cells than that in normal adult cells.
What happens when HER2 is overexpressed?
HER2 overexpression is directly correlated with poorer outcome in gastric cancer. In a study of 260 gastric cancers, HER2 overexpression was an independent negative prognostic factor and HER2 staining intensity was correlated with tumor size, serosal invasion, and lymph node metastases [33].
How does HER2 amplification promote cancer?
The HER2 receptor has an important role in normal cell growth and differentiation. However, amplification of the HER2 gene leads to overexpression of the receptor, which is linked to the development of many types of human cancers including breast, ovarian and those of the gastrointestinal tract [4, 5].
What are HER2 targeted therapies?
Anti-HER2 therapies (also called HER2 inhibitors or HER2-targeted therapies) are a class of medicines used to treat all stages of HER2-positive breast cancer, from early-stage to metastatic. Metastatic breast cancer is cancer that has spread to other parts of the body away from the breast, such as the bones or liver.
What drugs target HER2-positive?
Trastuzumab (Herceptin) and pertuzumab (Perjeta) are the most commonly used drugs used to treat HER2-positive breast cancer. Neratinib (Nerlynx) is another drug that is sometimes given after trastuzumab.
Which of the following HER2 overexpressing cancers have shown promise with targeted therapies?
Several HER2-targeted therapies are approved for the treatment of HER2-overexpressing breast cancer, and one such therapy is approved for gastric cancer. “HER2-targeted therapies have proven successful for patients with breast and gastric cancers.
Where is HER2 normally expressed?
HER2 is normally expressed on cell membranes of epithelial cells of several organs like the breast and the skin, as well as gastrointestinal, respiratory, reproductive, and urinary tract [17].
Which MoAb targets HER2 protein?
Trastuzumab, a humanized monoclonal antibody (MoAb) against HER2/neu (murine MoAb 4D5 combined with human immunoglobulin [Ig]G) that binds the ectodomain of the HER2 receptor, has been approved by the US Food and Drug Administration (FDA) for the treatment of HER2-overexpressing breast cancer in both the adjuvant and …
What is the difference between ERBB2 and HER2?
The HER2 is the legacy gene symbol for ERBB2 and may be more commonly used by the community; HER2 is also commonly used to describe the protein encoded by the ERBB2 gene. One unique feature of HER2 compared with the other receptors in the HER family is the absence of a known ligand.
What is ERBB2 amplification?
ERBB2 Amplification is a predictive biomarker for use of trastuzumab, lapatinib, pertuzumab, ado-trastuzumab emtansine, aromatase inhibitor, fam-trastuzumab deruxtecan, capecitabine, endocrine therapy, cisplatin, docetaxel, paclitaxel, carboplatin, fluorouracil, margetuximab, neratinib, pembrolizumab, pertuzumab/ …
What is ERBB2 mutation?
More recently, activating mutations in the ERBB2 gene have been increasingly reported in multiple solid cancers and were shown to play an oncogenic role similar to that of ERBB2 amplification. Thus, ERBB2 mutations define a distinct molecular subtype of solid tumors and serve as actionable targets.
What does ERBB2 stand for?
Receptor tyrosine-protein kinase erbB-2, also known as CD340 (cluster of differentiation 340), proto-oncogene Neu, Erbb2 (rodent), or ERBB2 (human), is a protein that in humans is encoded by the ERBB2 gene. ERBB is abbreviated from erythroblastic oncogene B, a gene isolated from avian genome.
Is HER2 overexpression a valid target in gastroesophageal cancer?
Expert opinion: HER2 overexpression is a validated target in gastroesophageal cancer, with therapeutic implications resulting in prolonged survival when inhibited in the front-line setting.
Is HER2‐amplification/overexpression associated with KRAS/BRAF in colorectal cancer?
One suggested anti‐EGFRresistance mechanism in colorectal cancer (CRC) is aberrant MEK–AKTpathway activation through HER2up‐regulation. We assessed HER2‐amplification/overexpression in stage II–IIIand IV CRCpatients, assessing relationships to KRAS/BRAFand outcome.
How is the her2kit used for HER2 overexpression?
FISH was carried out using the HER2Kit (Kreatech, Uckfield, UK) on 4 µm formalin‐fixed, paraffin‐embedded (FFPE) tissue sections from the tumours demonstrating HER2 overexpression by IHC, according to the manufacturer’s instructions.
Does HER2 overexpression increase the risk of recurrence?
There appears to be a greater difference in recurrence between those cases with HER2 overexpression and those showing no overexpression, although this is not significant in the group receiving chemotherapy.